Drug Trial Radar · NCT06674577
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept
Last checked: Nov 20, 2026Latest source record: Jun 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
750
Planned (sponsor's estimate)
Start
Dec 1, 2024
Primary completion
May 21, 2031
Study completion May 21, 2031
Sponsor
- Lead sponsor
- Vera Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 5, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to collect long-term safety and tolerability data for atacicept in patients with IgAN that completed Vera trial investigating atacicept in IgAN population.
Conditions
- IgA Nephropathy (IgAN)
- Renal and Urinary Disorders
- Berger Disease
Interventions
Atacicept 150 mgDrug
The atacicept drug product is available as a ready to use injection solution in the following prefilled syringe (PFS) that is composed of: \*BD Hypak™ SCF™ Barrel Glass barrel 1ml long with staked needle 27G ½" 5B with Rigid Needle Shield BD260 \*BD SCF™ Stopper 1ml long W4023 Flurotec
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events observed during the dosing periodTime frame: Baseline until end of study up to week156
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Vera Therapeutics
Brisbane, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.